Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM ESTGoldman Sachs analyst Salveen Richter raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $25.00) while maintaining a Neutral rating.
... MoreAcadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM ESTMizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining a Neutral rating.
The analyst commented, "Acadia has released top-line data for their pipeline asset trofinetide for the treatment of Rett syndrome. While... More
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM ESTOn December 6th, after market closed, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome.Acadia Pharma (NASDAQ: ACAD)
The... More
